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Abstract 
Lipid molecules are amphiphilic due to hydrophilic head-group and hydrophobic alkyl 
chain/s. Lipids are known to self-assemble into remarkable nanostructures in the 
aqueous medium. In order to enhance their applicability, these nanostructures are 
further stabilised into nanoparticles using various stabilisers; resultant are the oil-in-
water emulsions, which are common in many food and consumer products. Surfactant 
based stabilisers have been very popular; however, for particular applications the 
surfactant molecules are not completely beneficial. In this case, the solid materials are 
employed to obtain surfactant-free emulsions also called Pickering (or Ramsden 
Pickering) emulsions. Natural and synthetic clays, silica nanoparticles and 
hydrocolloids have been used for this purpose. Carbon nanotubes (CNTs) have received 
noteworthy attention due to their unique structural, physical and electrical properties. 
These properties allow use for a huge range of applications, of which this thesis will 
outline. In the past, the hydrophobic surface of CNTs have limited their potential in 
many fields, as well as their tendency to aggregate in most solutions, leading to large 
amassed particles which prove near-impossible to disperse. The ability to stabilise lipid 
and CNTs would benefit several areas and applications such as drug delivery and gene 
therapy. With the techniques in the following report, however, the study has proven that 
the combination of Dimodan U (DU) and CNTs can form stable nanostructured 
dispersions, which remain homogeneous for several months. This idea proposes a new 
way to delivery simple drugs and by tweaking the nanostructure, through alteration of 
the ratios of CNT to lipid, these systems could be used in targeting different organs. 
  
 
Graphical Abstract: Internally Nanostructured Lipid Particles Stabilised by Surfactant 
and Carbon Nanotubes for drug loading. 
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Chapter 1: Introduction 
 
Understanding the relationship between structure and function of materials is of the 
utmost importance in the modern scientific community. Nanomedicine is an emerging 
discipline, likely to revolutionise our lives in general, and health in particular. It defines 
as the ability to manipulate matter at the nanoscale (0.1 nm to 1000 nm) and has 
resulted in several new materials, products, and devices that show original and 
unfamiliar behaviour. Nanomedicine is now a widely used term, which refers to all 
nanomaterials, nanoparticles, and nano-composites used for biomedical purposes, which 
implies the medical application of nanotechnology and related research lead in to the 
designing, testing, and optimizing of the pharmaceutical formulations [1] 
Nanotechnology is the science of particles in the nanoscale range (1 nanometre to 1 
micrometre) having unique properties, which change when the size of the particles as 
well as the melting point, electronic and optical properties are altered extensively [2,3]  
 
1.1 Carbon Nanotubes 
In this nanotechnological development, carbon nanotubes (CNTs) have attracted a great 
deal of attention. Bacon, in 1950, is recorded for discovering the first CNTs but at that 
time they were not fully appreciated. It was not until 1991, when Iijima, a Japanese 
researcher, described the CNTs and proposed them as an exciting new material for drug 
delivery as novel carrier systems, due to their unique structural properties [4] (Iijima S, 
1991). A Carbon Nanotube can be defined as carbon atoms arranged in a series of 
condensed benzene rings or graphite sheets rolled up into a cylindrical structure. Along 
with diamond and graphite, these materials belong to the fullerenes family. CNTs are 
completely insoluble in water and are biologically non-degradable. CNTs can be sub-
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classified into Single-walled carbon nanotubes (SWCNTs), and Multi-walled carbon 
Nanotubes (MWCNTs). 
 
1.2 Properties and Advantages of Carbon Nanotubes 
Mehra et al (2008) stated that the increase in the use of CNTs was due to their 
outstanding mechanical strength, as well as thermal conductivity, biocompatibility and 
ultra-light weight. These traits, as well as their high surface area available for 
functionalization, make them extremely competent to use in a huge range of industrial 
and medicinal sectors. [1] 
 
The same paper, also reported by Jain et al (2007), listed the following as advantaged 
CNTs may offer over other colloidal systems [3]. These include traits such as 
biocompatibility and non-immunogenic nature, non-biodegradable, highly elastic 
nature. Intracellular delivery is also possible, and, on the basis of in-vitro tests, exhibit 
minimum cytotoxicity. CNT toxicity is a topic fiercely debated, but the study also 
suggests that 96% is excreted by urine and remaining 4 % by faeces [1]. CNTs have an 
ordered structure with high aspect ratio and do not break down during processing as 
carbon fibres do so easily, despite being ultra-light weight. It has open end on both 
sides, which makes the inner surface accessible and subsequent incorporation of species 
within nanotubes is particularly easy. Nanotubes have longer inner volume relative to 
diameter of nanotubes for entrapment. CNTs are able to enter cells by spontaneous 
mechanism due to its, tubular and nano-needle shape. It has distinct inner and outer 
surface, which can be differentially modified for chemical or biochemical 
functionalization. 
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1.3 Drug Delivery using Carbon Nanotubes 
The advances in nanotechnology and nano-medicine have enabled ground-breaking 
solutions in the field of drug delivery. Whereas conventional chemotherapeutic drugs 
often cause severe side effects and are not tumour-specific, nanoparticles preferentially 
accumulate in tumours through the “enhanced permeability and retention” (EPR) effect. 
In comparison to their small-molecule counterparts, nanoparticle drugs have proved to 
have higher intratumoural drug concentration and lower normal-tissue concentrations 
[5]. Additionally, nanoparticles, which contain high surface area-to-volume ratios, can 
be potentially engineered to carry tumour-targeting molecules, tissue permeation 
enhancers, two or more types of therapeutics for more efficient cancer treatment [39].  
Carbon nanotubes (CNTs) offer opportunities for chemotherapy drug delivery. 
Structurally, CNTs can be viewed as a tube rolled from layers of graphene sheets. CNTs 
can then be further sub-categorised depending on the number of sheets. CNTs that have 
only one layer of graphene are classified as single-walled carbon nanotubes, whereas 
multi-walled carbon nanotubes are CNTs with multiple layers of graphene. Due to their 
ordered structure, CNTs show outstanding physical traits, including ultra-high surface 
area, high aspect ratio, high tensile strength [7,8,9], excellent optical [10], electrical and 
thermal properties [11,12,13]. It has been found that CNTs easily penetrate all sorts of 
cells, including cells thought to be hard to transfect [14]. CNTs are being widely 
explored for potential biological applications because of their size, unique shape, and 
structure, as well as their physical properties. 
CNT toxicity is a field that is heavily under research, both in vitro and in vivo. Studies 
have proven that that appropriately functionalized CNT, e.g. polyethylene glycol (PEG) 
functionalized CNT does not cause noticeable toxicity to the treated animals [15]. Bio-
distribution of the lipid-polymer, phospholipid-PEG (PL-PEG), functionalized SWCNT 
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showed that CNTs are safe due to their ease of excretion via the biliary and renal 
pathways after intravenous injection [16,17]. These results have paved the way for 
applications of CNTs in cancer therapy. Recently, SWCNTs have been used in a variety 
of biomedical applications extending from cancer drug delivery to tumour imaging and 
detection [13]. 
Since CNTs are pre-formed supramolecular nanotubes, the drug loading to this structure 
can prove to be extremely difficult. SWCNTs can be filled with a large variety of 
compounds, including organic molecules [14,15] and inorganic materials. [16,17] 
Chemotherapeutic drugs have been previously loaded into the interior of SWCNTs 
using a capillarity-induced filling. However, the loading amount is below 5% (w/w) 
[18]. This being a rather small percentage, researchers have also investigated the 
loading of small molecule drugs directly onto the CNT surface. It was discovered that 
pre-functionalized CNTs have large surface areas, which allows for direct attachment to 
some hydrophobic drugs that contain flat benzene ring structures. One of these studies 
investigated the adsorption of doxorubicin onto a SWCNT surface [19]. This method 
could yield a very high loading amount (400% by weight). When the drugs are loaded 
directly into a CNT, the CNT-coating polymers are freed for conjugation from other 
functionalities, e.g. targeting molecules, antibodies, fluorescence molecules or other 
drugs for multifunctional delivery [19]. However, drugs such as paclitaxel, with a bulky 
structure, do not absorb drugs especially well and as a result; the subsequent 
formulations are not stable.  
Drug delivery in conjunction with CNTs is a new technology in the pharmaceutical 
science. As stated before, CNTs have a great potential in this regards for the delivery of 
drugs, antigen, vaccines. Several studies have shown the many benefits regarding the 
use of these materials in a medicinal use.  
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Liu et al., 2007 studied the arginine-glycine-aspartic acid (RGD) peptide and 
Polyethylene glycol (PEG) functionalized Single walled carbon Nanotubes (f-SWCNTs) 
on the delivery of doxorubicin, which is an anticancer drug. The in-vitro release profile 
revealed no toxic effects on the cancer cell, and shows the drug release was pH and 
diameter dependent. They also reported the CNT-doxorubicin transporter led to 
targeting and show inhibition of specific cells, which could open a new opportunity in 
cancer chemotherapy. [20] 
 
A report by Yu et al., 2007 described the releasing and in-vitro activity of 
gonadotrophin-releasing hormone (GnRH) from the modified MWCNTs in cancer cells. 
GnRH plays a pivotal role in the regulation of the pituitary/gonadal axis and 
reproduction. This hormone is used as a targeting ligand to its receptors, which are 
overexpressed in the plasma membrane of different types of cancer cells. This study 
proved that GnRH-CNTs modify uptake receptors and also aid making GnRH-CNTs 
toxic to cancer cells. [21] 
 
 Pantarotto et al., 2004 reported the delivery of plasmid DNA from the functionalized 
CNTs for gene therapy. The study revealed the better response and was internalized 
within the mammalian cells and delivery of the DNA in to the cells. [22] In earlier 
works by Pantarotto and his team, it was reported the cellular uptake of free peptides 
and oligodeoxynucleotides is extremely poor. Because of this, conjugation of these 
molecules onto CNTs surfaces may allow improvements in the delivery of such 
biological molecules. Functionalized SWCNTs have been the focus of several studies 
for vaccine delivery, in this case by 1, 3 dipolar cyclo-addition attaching a small peptide 
sequence for the foot and mouth disease virus (FMDV). SWCNTs-FMDV peptide 
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complex induced a better antibody response and no cross reactivity was observed in-
vivo for SWCNTs-FMDV conjugate. [23] 
 
1.4 Functionalization 
In covalent functionalization techniques, modifications to the sidewall and to the ends 
are the two major techniques for the surface alteration of CNTs. Ends and defects are 
more reactive than sidewall functionalization. In covalent functionalization, more 
functional groups could be generated at the ends or sidewall of surface of CNTs such as 
carboxylic acids, ketone, alcohol etc. Additionally, several functional groups could be 
generated on the sidewall surfaces without loss of Von Hove singularities.  
 
In the non-covalent functionalization techniques various types of surfactants, polymers 
and biopolymer (nucleic acids and peptides) have been used. Surfactant adsorption at 
interfaces has been widely studied because of its importance in detergents, lubrication, 
and colloid stabilization [24]. CNTs are insoluble in most solvents [25] and especially 
in water, but, with the addition of 1% solution of anionic surfactant SDS, have been 
reported to form stable black suspensions when sonicated [26]. When SDS is adsorbed 
onto a surface, it creates a distribution of negative charges that prevents their 
aggregation and induces stable suspensions in water. Several different possible 
orientations of the SDS molecules can be envisioned on the surface of CNTs. For 
example, the SDS molecules can be oriented perpendicularly to the surface of the 
nanotube, forming a monolayer [27,28]. However, according to previous studies into 
molecular organization, two other arrangements are possible for the surfactant at the 
solid-liquid interface. In these cases, the hydrophobic part of the SDS is connected to 
graphite by weak van der Waals interactions, and the hydrophilic end of the surfactant is 
oriented toward the aqueous phase, forming half-cylinders on the surface of the graphite 
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plane [29,30,31,32]. Because CNTs are rolled-up graphene sheets, the SDS molecules 
may also form similar half-cylinders on the surface of the tubes. These can either form 
parallel or perpendicularly to the tube axis. 
 
Nanomedicine has also developed in the field of cell biology, with the increased 
research into nanosized particles such as Liposomes [33] In recent years, Particulate 
drug carriers including oil-in-water (O/W) emulsions, liposomes, microparticles and 
nanoparticles based on synthetic polymers or natural macromolecules have been the 
centre of many studies [34]. The O/W emulsions have been introduced successfully to 
the clinic for parenteral nutrition in the fifties. Based on these emulsions for parenteral 
nutrition, drug-containing emulsion formulations have been developed, e.g. containing 
diazepam and etomidate [35]. For some products, Diazemuls and Diazepam-Lipuro of 
note, these liposomes are sometimes only used to reduce or eradicate the side effects. In 
the case of Diazepam, liposome emulsions are used to reduce the pain of injection and 
inflammation at the injection site. Despite the excellent tolerability of these O/W 
emulsions the number of products on the market is relatively low, indicating a fairly low 
success in this research. The main reason for this limited success and the consequent 
lack of marketable products is the emulsion’s instability, which can be caused by the 
incorporated drug.  
 
 
1.5 Functionalized Carbon Nanotubes (f-CNTs) for drug delivery  
 
CNTs exhibit unique structural, mechanical, and electrical properties and are intensely 
studied for possible use in many fields [36,37]. One approach that is currently being 
considered is the functionalization of their surface. To the current day, there have been 
several successful strategies using covalent chemistry that have been applied to the 
sidewall derivatization of CNTs. The single issue only being that this can alter their 
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inherent properties [38,39]. Thus, the prospect of functionalizing their outer surface in 
non-covalent ways through the chemical adsorption [40,41]. seems like a very attractive 
option. f-CNTs are useful in multiple ways. For one, it improves the solubility of CNTs, 
which are completely insoluble in aqueous solutions. It also helps to reduce the 
aggregation behaviour of individual tubes. It could provide the efficient intracellular 
uptake and improved efficacy, which enhance the internalization of CNTs within cells 
due to its nano-needle shapes as well as increasing the possibility of the attachment of 
various functional groups onto the surface of CNTs.  
1.6 Lipids, liposomes and Isasomes 
Phospholipid vesicles, rediscovered as ‘liposomes’ in 1965 by Bangham, found their 
way to the cosmetic market in 1986 [42] as the anti-aging product Capture (Dior). This 
helped smooth the way for liposome-based pharmaceutical products. By the beginning 
of the nineties, the first pharmaceutical products came to the, and included the synthetic 
lung surfactant Alveofact (Dr Karl Thomae GmbH/Biberach in Germany) for 
pulmonary instillation, Epi-Pevaryl, a topical product for anti-mycotic therapy (drug: 
econazole) and other products for intravenous injection (e.g. Ambisome with 
amphotericin and cytotoxic-containing formulations like Doxil and Daunosome) [34]. 
This being said, the total number of products on the market is still quite limited. One of 
the reasons for this–apart from possible technological problems–is the non-availability 
of a ‘cheap’ pharmaceutical liposome. 
The number of products based on polymeric microparticles on the market is low. After 
the introduction of the first wave of products, there was only a slight increase in the 
number of microparticulate products. The situation worsened for polymeric 
nanoparticles, after more than 30 years of research; this delivery system still practically 
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does not exist. An exception is the product Abdoscan produced by the company 
Nycomed, however, this is not a formulation for chronic treatment. Rather, it is a 
diagnostic agent. [43] 
Liposomes are a form of vesicles that consist either of many, few or just one 
phospholipid bilayers. The polar character of the liposomal core enables polar drug 
molecules to be encapsulated. Amphiphilic and lipophilic molecules are solubilised 
within the phospholipid bilayer according to their affinity towards the phospholipids. 
Liposomes have the advantage of being both non-toxic and biodegradable because they 
are composed of naturally occurring substances. Materials that are encapsulated within 
liposomes are perfect for use in drug carrier systems as they are protected to varying 
extent from immediate dilution or degradation. These materials also have the unique 
ability to entrap drugs both in an aqueous and a lipid phase, making such delivery 
systems attractive for hydrophilic and hydrophobic drugs. Recently, high-entrapment 
efficiencies are becoming more possible, due to advancements in the methods of 
preparing and formulating liposomes, creating a tremendous pharmaceutical impact. 
Additionally, such encapsulation has been shown to reduce drug toxicity while retaining 
or improving the therapeutic efficacy. Several studies have claimed the use of liposomes 
as drug carriers aid in the treatment of cancer, [34,35] leishmaniasis,[42] metabolic 
disorders, and fungal diseases.[43] 
 
Making up a large and diverse group of naturally occurring organic compounds, lipids 
play an essential role in the cell membrane structure. Although there is great structural 
variety among the lipids, with fats, phospholipids and steroids all being a part of the 
family, they are related by their insolubility in water, and their solubility in non-polar 
organic solvents such as ether, chloroform and benzene [44,45]. Phospholipids are one 
of the major groups of the four membrane lipids. These phospholipids are derived from 
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the three-carbon alcohol, glycerol, or from sphingosine. The common alcohol 
components of phospholipids derived from glycerol are called phosphatidylserine (PS), 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), 
and phosphatidylinositol (PI). Due to inexpense and readiness in bulk, phospholipids are 
very commonly used in the preparation of lipid vesicles and already have very well 
established and characterized preparation techniques. They occur through an 
esterification process of one of the primary hydroxyl groups of glycerol to phosphoric 
acid through its hydroxyl group. The two remaining hydroxyl groups of the glycerol 
backbone form the non-polar tail end of the lipid by esterification to either saturated or 
unsaturated fatty acids and form the non-polar tails of the lipid. [45] 
 
Lipids are a naturally occurring surfactant group that form non-covalent aggregates in 
the presence of an aqueous environment like water [46]. Liposomes are the most known 
structures composed of lipids curled into spherical shells in an aqueous environment 
[47]. Very similar to lipid bilayers that form the cell membrane, they share many 
dimensional, structural and functional properties [48]. 
 
Both liposomes and cell membranes can be described by the “fluid mosaic model”, 
which was proposed in 1972 by Singer and Nicholson [49]. The model states that, as the 
head groups are hydrophilic, they can be left exposed to the aqueous environment while 
the hydrophobic lipid tails can orientate towards each other. As a result these lipids 
spontaneously organise in concentric spheres and sheets of bilayers when dispersed in 
water. However, they may assemble into other types of structures, called meso-
structures rather than vesicles under specific conditions [50,51]. The size and shape of 
the resulting aggregates mostly depend on geometry of the lipid, as well as its chemical 
properties and the physical conditions (e.g. temperature, pH and salinity). In addition to 
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these properties, attractive-repulsive forces (DLVO Theory) and thermodynamic 
interactions have a role in the vesiculation process, due to the amphiphilic and ionic 
properties of the lipids [52]. The self-assembly of lipids to vesicles relies on two main 
phenomena, the theory of spontaneous vesiculation and the curvature theory, dominated 
by the physiochemical properties of the phospholipids such as lipid head group, tail 
length and saturation level [53]. 
 
Isasomes are ordered colloidal systems, i.e., nanometre-sized droplets, which are 
dispersed and stabilised as aqueous emulsions with self-assembled internal structures. 
These structures can organise in several different ways: fluid isotropic water-in-oil 
(W/O) microemulsions (L2 phase), or liquid-crystalline mesophases, including 
bicontinuous cubic, hexagonal, and discontinuous micellar cubic. 
 
Isasomes are usually stabilized by surfactants, such as Pluronic F127, or block 
copolymers. However, such O/W emulsions are also known to be stabilized by proteins 
and nanoparticles, the latter are called Ramsden–Pickering or Pickering emulsions. 
Isasomes and other nano-structured dispersions find applications in a wide range of 
fields, ranging from pharmaceutics to foods. The internal structure of Isasomes can be 
tuned by varying the δ value into cubic, hexagonal or even fluid isotropic structures,  
Bulk liquid crystalline phases can be detected via rheological techniques thanks to their 
characteristic viscosity, which can be determined by the amount of dispersed 
(hydrophobic) phase. This viscosity can be further adjusted by adding hydrogelling 
agents to the continuous water phase. In this way, the Isasomes can be entrapped into a 
thermoreversible hydrogel network which may help controlling uptake and release rates 
by Isasomes.[53] 
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Chapter 2 
Materials 
Single-walled carbon nanotubes (SWCNT) and multi-walled carbon nanotubes 
with -OH functionalization (MWCNT-OH) were obtained from Nanoamor 
(Houston, USA) whereas –COOH functionalized multi-walled CNTs (MWCNT-
COOH) were purchased from Sigma-Aldrich (Athens, Greece). The lipid, 
Dimodan U/J (DU) was a generous gift from Danisco (Brabrand, Denmark). It is 
a commercial product containing more than 98% monoglycerides. The triblock 
copolymer pluronic F127 (PEO99-PPO67-PEO99) was purchased from Sigma-
Aldrich, UK. All solutions were prepared with Millipore water.  
 
Methods 
2.1 Ultrasonication  
The stable nanostructured systems were prepared by Ultrasonication using the 
ULT065 from Ultrawave on samples made from pre-dispersed solutions of CNTs 
and Dimodan U (DU) lipid that had been gently heated to slightly above room 
temperature for ease of use. The lipid was then added to the bottle of the 
container before adding the CNT-solution and ultrasonicating at 40% amplitude 
for two minutes without pulsating. 
2.2 Dynamic Light Scattering 
Dynamic Light Scattering (DLS) is a technique using the intensity of light 
scattered by the molecule as a measurement of time. When light is scattered by a 
molecule or particle some of the incident light is scattered. If the molecule was 
stationary then the amount of light scattered would be a constant. However, since 
all molecules in solution diffuse with Brownian motion in relation to the detector 
there will be interference (constructive or destructive) which causes a change in 
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light intensity. By measuring the time scale of light intensity fluctuations, DLS 
can provide information regarding the average size, size distribution, and 
polydispersity of molecules and particles in solution. The faster the particles 
diffuse, the faster the intensity will change (if the light was bright enough this 
would be seen as a twinkling effect). The speed of these changes is thus directly 
related to the motion of the molecule.  
 
Particle sizes in suspension were determined by dynamic light scattering (DLS) 
using a Malvern Instruments Zetasizer Nano-ZS and Malvern DTS version 5.00 
software. Samples were ran 10 times, and an average being taken. This was 
repeated 5 times instantly after, all using a ZEN0118 cuvette (also from Malvern)  
2.3 Small Angle X-ray Diffraction 
CNT, lipid and CNT-lipid samples were dehydrated using nitrogen gas followed 
by vacuum drying in the desiccator for about 20 minutes. XRD measurements 
were carried out on a Bruker D2 phaser utilising its 0.1mm slit and a 0.1mm knife 
edge distance, allowing more accurate results. Samples were measured on the D2 
phaser, at both low angle as well as higher angle, 1.2-10 degrees and 5-50 
degrees, respectively, and analysed on the DIFFRAC.SUITE software. Samples 
were measured for 20 minutes for both low and high angles. 
2.4 Raman Spectroscopy 
CNT, lipid and CNT-lipid samples were dehydrated using nitrogen gas followed 
by vacuum drying in the desiccator for about 20 minutes. Spectroscopic 
measurements were carried out on a Horiba Jobin-Yvon LabRAM HR800 
spectrometer. A 532 nm laser was utilized to collect spectra from 100 – 4000 cm-
1 using a grating of 600 g mm-1 and blazed at 750 nm. Spectra were acquired 
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using x50 long working distance objective with a numerical aperture of 0.50. The 
confocal hole was set at 100 μm for spectral collections. The detector used was an 
Andor electromagnet (EM) charged coupled device (CCD). A video camera with 
the Raman system was used to guide spectral collection. All spectra were 
collected with sample situation on Calcium Fluoride slides (Crystran, UK). The 
instrumentation was calibrated before operation to silicon at the spectral line of 
520.8 cm-1. Spectra were acquired using the 532 nm laser at 1 % exposure for 10 
seconds and accumulated 5 times. Immediate data interrogation and manipulation 
was carried out on the raw data using the LabSpec 6 spectroscopy software suite 
(HORIBA Scientific).  
2.5 Freeze-drying 
In order to measure our samples more easily on Raman and other spectroscopic 
techniques, samples were freeze-dried using an Alpha 2-4 LD Plus from Christ. 
This model has vacuum control for optimization/reduction of process times and 
temperature monitor. 1mL flasks of several samples were placed in the freeze 
dryer and left for 3 days until all water was removed, leaving a darker ‘fluffy’ 
solid, which absorbs water from the air over time, once removed from the freeze 
dryer. 
2.6 Contact Angle 
To measure the contact angle of water on the CNT surface, a FTA1000 B Class 
from First Ten Angstroms (FTA) was utilised. Water was dropped from a 
dropping pipette onto the flat surface of CNT and pictures were taken upon 
contact with the surface. The angle of contact was then measured through FTA 
software to provide information of the hydrophobicity of the sample. 
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2.7. UV-Vis Spectroscopy 
To measure our drug encapsulating samples’ drug release, a UV-3600 UV-Vis-
NIR Spectrophotometer from Shimadzu was used. Samples were run for 24 
hours, measuring once every 30 minutes between 200nm-1 and 400 nm-1. 
Equipped with a high performance double monochromator, ultra-low stray light 
is achieved at high resolution. 
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Chapter 3: Nanostructured lipid particles: Preparation, 
Stability and Characterization 
 
3.1 Isasomes with F127  
Isasomes, F127 and lipid in water, were formed via the ultrasonication of lipid in the 
presence of a solution of Pluronic F127. F127 was used as it is a known stabiliser which 
is also very common and cheap to use. These isasomes were very stable, opaque and 
white. The solution of surfactant F127 was prepared by simply stirring 200 mg of 
surfactant in 100 ml water. 9.5 ml of each of above solutions was then added to 500 mg 
of molten DU in a glass vial. The mixtures were then subjected to ultrasonication and 
were allowed to cool down (about 10 minutes) prior to further use. 
 
3.2 Dispersion of Carbon Nanotubes 
CNTs, on their own, are not known to disperse for extended periods of time in water. 
First, powdered CNTs (MWCNT-OH, MWCNT-COOH and SWCNT) were dispersed 
in 100 ml water using probe ultrasonicator (ULT065 from Ultrawave, Cardiff, UK) at 
40% power for 2 minutes without pulse. CNTs were stable on their own (without lipid) 
during preparation time (for about 20 minutes). 
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Figure 1: Photographs of nanotubes in Millipore water taken after 30 minutes 
after A) stirring on a hot plate at room temperature for 2 minutes and B) 
ultrasonicated at 40% power for 2 minutes without pulse. 
3.3 CNT-Lipid Nanostructured Particles with varying F127 and CNT 
ratios 
CNTs and Lipids were put to use together, and were able to form stable emulsions when 
used in conjunction. A wide range of ratios of F127:CNT were used, from 100:0 to 5:95 
and finally using purely CNTs alone to compare how stable the emulsions are. These 
emulsions proved stable at all ratios between 100:0 and 5:95. There are complications 
for stabilising with only CNTs, with the complete absence of a stabiliser like F127 
which are detailed in future. Despite the difficulties, it is possible to stabilise after 
optimization steps. 
 
3.4 Characterization of CNT-Lipid Nanostructured Particles 
Raman spectroscopy revealed COOH-functionalized CNT-lipid interactions responsible 
for their mutual stabilization in aqueous solutions Figure 2. The CNT spectra contain 
typical Raman graphite bands; the G band is assigned to the in-plane vibration of ‘C-C 
bond’, the D band (not shown) is activated by the presence of disorder in carbon 
systems and the G’ band attributed to the overtone of the D band. Upon interaction and 
formation of CNT stabilized lipid particles the G and G’ bands display a blue shift (shift 
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to higher wavenumbers). Table (1)  lists the peak centres for characteristic bands from 
pure CNTs and nanostructured lipid particles containing CNTs. A blue shift, in case of 
CNTs, is a result of either or a combination of the following: 1) the dispersion of CNTs, 
as opposed to a bundled state when pure 2) coating of CNTs; Douroumis et al.[54] have 
shown significant blue shifts when analysing lipid coated SWCNTs and suggest that the 
presence of functionality affects the symmetric radial vibrations of the hollow cylinders 
through stiffening which are attributed to the interactions between the CNTs and the 
lipid molecules 3) subjecting CNTs to a high pressure. [55] 
 
 
Figure 2: Original spectral plot showing the averaged Lipid, MWCNT-COOH and 
combined nanostructure. MWCNT-COOH and MWCNT-COOH Lipid nanostructure 
have both been vector normalised and offset for visual clarity. The dotted lines on the 
peaks correspond to the Raman Shifts seen in different bands. 
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Figure 3: Original spectral plot showing the averaged Lipid, MWCNT-OH and 
combined nanostructure. MWCNT-OH and MWCNT-OH Lipid nanostructure have 
both been vector normalised and offset for visual clarity. The dotted lines on the peaks 
correspond to the Raman Shifts seen in different bands. 
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Figure 4: Original spectral plot showing the averaged Lipid, SWCNT and combined 
nanostructure. SWCNT and SWCNT Lipid nanostructure have both been vector 
normalised and offset for visual clarity. The dotted lines on the peaks correspond to the 
Raman Shifts seen in different bands. 
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Figure 3 displays notable spectral peaks at 1578.23cm-1 and 2683.72 cm-1, displaying 
tell-tale signs of multiple walls in the Carbon Nanotube, as can be seen by comparison 
to the SWCNT single peak in that area in Figure 4. In the Lipid Nanostructure spectra 
in Figure 2, the CNT peaks can be seen, however they appear 21.83 cm-1 and 36.36 cm-
1 shifted, known as a blue shift. This could be caused by Hydrogen bonding affects, 
which would be more apparent in –OOH than other CNTs. This is backed up by the 
amount of shift seen, as shorter shifts are seen in MWCNT-OH and shorter still in 
SWCNT. 
 
Table 1: Raman wavenumbers and shift for CNTs and nanostructured lipid particles 
with CNTs 
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Figure 5: Particle size of nanostructured lipid particles (A) An average particle size of 
CNT stabilized nanostructured lipid particles was in the range of 2-5 μm and it was 
comparable to the size of lipid particles stabilized by Pluronic F127 surfactant (B), as 
determined from dynamic light scattering experiments. An additional peak for 
surfactant based system could be attributed to surfactant micelles of about 100 nm size. 
The different colours represent duplicate runs for each sample, for more accurate, 
repeatable data. 
 
Once stabilised NanoLCPs were established, particle size was measured using a 
Malvern Zetasizer to see uniformity and to compare to common stabilisers such as 
Pluronic F127. Figure 5a shows DLS data for a Carbon Nanotube stabilised lipid 
nanostructure whereas Figure 5b shows its F127 counterpart, outlining the differences 
between the two methods of stabilization.   
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Figure 6: Contact Angle measurements for a) MWCNT-OH b) SWCNT and c) 
MWCNT-OOH 
 
Contact Angle measurements were performed in an attempt to quantify the wettability 
of the CNT surface and to ascertain the hydrophobicity or hydrophilicity of the surface, 
to perhaps determine which CNT is most likely to stabilise best, due to any 
functionalization on the surface. Figure 6 shows the contact angle of each CNT surface 
and points us to believe that MWCNT-COOH is the most hydrophilic, the contact angle 
is nil, compared to larger contact angles seen in the MWCNT-OH and SWCNT. These 
results however, must be taken with a pinch of salt due to the difficulty of making these 
CNT surfaces completely flat, and not knowing about the surface of the CNT pellet, 
after being pressed. As well as this, each pellet may have been pressed with a slightly 
different force which may damage the accuracy of such tests. 
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Figure 7: XRD pattern for dry lipid, Pristine MWCNT-COOH, freeze-dried lipid 
nanostructure with CNT and the same nanostructure, stabilised by F127. The red plot 
represents the XRD pattern for lipid alone, showing a lamellar pattern. Similar results 
can be seen for the green and purple lines, representing freeze-dried lipid nanoparticles 
stabilised with CNT-COOH and F127 surfactant, respectively. The blue line, which 
shows the plot for CNT-COOH alone, shows no notable peaks. The absence of the 
lamellar phase is due to Carbon Nanotubes having little diffraction pattern on XRD at 
this range. 
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3.5 CNT-Lipid Nanostructured Particle stability 
Nanostructured Lipid-CNT particles (NanoLCP) with various concentrations of DU and 
CNTs, as well as some samples containing Pluronic F127 (a known stabiliser) were 
prepared via ultrasonication, using various amplitudes (AMPL), pulse settings and also 
varying time. These settings and concentration ratios vastly affect the stability of the 
NanoLCP, with some destabilising almost instantly, to some completely stabilising for a 
period of roughly 3 to 4 months. Once showing signs of destabilization, these 
NanoLCPs return to their homogeneous state after lightly shaking. Figure 8 shows the 
destabilization and restabilization of such structures, whereas Figure 9 highlights a few 
significant ratios of CNTs, DU and water. 
 
Figure 8: The stability of a CNT-Lipid nanostructured particle over a 3 month period. 
The ’10 minutes’ sample had been ultrasonicated 10 minutes prior to the photograph. 
The same sample was then photographed after 2 days, 2 months and 3 months to 
represent the ongoing stability over several months.   
 
Figure 8 also shows the ease of which these nanostructures can be re-dispersed and 
regain stability. This could be a very useful property for further use, bringing in the idea 
of ‘shake-and-use’ nanostructures, adding greatly to their shelf-life. 
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Chapter 4: Optimization and Generalization  
 
4.1 Optimizing the ratio for MWCNT-COOH 
Optimization of these systems is very important in order to reach the full potential of 
this technique of drug delivery. In order to do this, research had to be done to ensure we 
had the most stable region. Using Raman Spectroscopy to monitor a range of stable 
CNT-lipid nanostructures, we can observe any changes in peak heights, or any shifts 
that take place. 
 
Figure 10: Original spectral plot showing the averaged MWCNT-OOH at different 
concentrations to show the peak progression. The spectra have been vector normalised 
and offset for visual clarity. The dotted lines on the peaks correspond to the Raman 
Shifts seen in different bands. 
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Figure 10 is a spectral plot showing the stable region of MWCNT-OOH in lipid. As the 
amount of CNT in the sample increases, certain peaks appear stronger, which again 
match up to the peaks for native CNTs. This not only shows that there is in fact more 
CNTs in the nanostructure, but also suggests that stable nanostructures can exist at 
different ratios. This could prove important if a certain drug needs more or less CNTs 
than another to be released at the right time. From repeating this for different 
concentrations of CNTs, Figure 9 was produced, showing a rough guideline to the 
upper and lower limits to the process. 0-2.5ug/mL did not have enough CNTs to 
stabilise the Lipid for even short lengths of time, whereas the column labelled ‘Excess 
CNTs’ showed stable lipid, with aggregated CNTs on the surface, or floating in 
solution. For MWCNT-OOH, the range of stable concentrations of CNTs are shown 
between 3 and 5ug/mL. 
 
 
Figure 9: The stable, excess and insufficient zones of CNT:Lipid ratio for MWCNT-
OOH 
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4.2 Optimizing the ratio for differently functionalized CNTs 
With this information on MWCNT-OOH, we can expand our study to include different 
Carbon Nanotubes, namely MWCNT-OH and SWCNT. Using the same ratios as 
before, MWCNT-OH showed very similar results for stability, as can be seen in Figure 
12. SWCNT, however, needed far fewer CNTs in order to stabilise. Using roughly 10% 
of the amount needed for MWCNTs with both –OH and –OOH functionalization. 
 
Figure 11: Original spectral plot showing the averaged SWCNT at different 
concentrations to show the peak progression. The spectra have been vector normalised 
and offset for visual clarity. 
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Figure 12: Original spectral plot showing the averaged MWCNT-OH at different 
concentrations to show the peak progression. The spectra have been vector normalised 
and offset for visual clarity.  
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Figure 13: The stable, excess and insufficient zones of CNT:Lipid ratio for MWCNT-
OH and SWCNT 
4.3 Toxicity  
It is likely that occupational and public exposure to CNT-based nanomaterials will 
increase dramatically in the near future. Hence, it is of the utmost importance to explore 
the yet almost unknown issue of the toxicity of this new material. The research is 
lacking, however, there are some reports stating that doses of 400ug/mL are the upper 
limit of toxicity, and causes cell death [56] 400ug/mL corresponds to roughly 10 million 
CNTs per cell, a figure this report is far below. As well as this, CNTs have been 
observed to have enhanced solubility when functionalized with lipids which would 
make their movement through the human body easier and would also reduce the risk of 
blockage of vital body organ pathways. Drug encapsulation has been shown to enhance 
water solubility, better bioavailability, and reduced toxicity. [57] 
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4.4 Dehydration and re-dispersibility 
 
Figure 14 shows the process of freeze-drying and re-dispersing the CNT-Lipid 
Nanostructure with the use of a freeze-dryer. 
 
Samples can be subjected to freeze-drying and can be stabilised once more by simply 
shaking with the equivalent water. The third screw-top vial shows the sample 
immediately after shaking to re-disperse. A layer of foam can be seen, however 
disappears when left to settle, leaving the sample completely dispersed and 
homogeneous, almost identical to the original sample. This is a very useful property, as 
the freeze-dried samples can easily be stored and re-dispersed when required, for use 
immediately.  
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4.5 Fine tuning lipid content 
 
Figure 15 shows the effect percentage of lipid has on the stability of the nanostructure. 
 
Samples containing 2, 5, 10, 15 and 20% lipid content were studied to monitor the 
limitations and capabilities of the different percentages. 2%, 5% and 10% all easily 
formed stable CNT-stabilised lipid nanostructures in 10mL. However, 15% and 
upwards formed very thick unstable emulsion, which could be due to the viscosity 
affecting the power of the Ultrasonication process. From these results, the attention was 
kept on 2-10% lipid, with 5% being the main focus to reduce costs and amount of lipid 
and CNTs needed per sample. 
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Chapter 5: CNT-stabilized Nanostructured Lipid Particles for 
Drug Delivery 
 
5.1 Drug loading 
Using the table of stable systems reported in the previous chapter, Aspirin can be 
encapsulated in the nanostructure with a simple method of stirring. 5um of Aspirin is 
added slowly to the already stabilised structure, shaking the container thoroughly 
between each miniscule addition. 
 
 
Figure 16: Stable CNT-Lipid nanostructure is shown in the first part of the image. The 
second showing no difference in stability of nanostructure after stirring.  
 
Figure 10 shows a list of stable CNT-Lipid nanostructured particle ratios, to which 
Aspirin can be added and simply stirred in, as shown in Figure 16. The stability of 
these new drug-encased nanostructures remain consistently over 2 months, with the 
only visible difference being a slight colour change, with the new system slightly lighter 
than its counterpart. 
The foam that can be seen in the second image does eventually clear, leaving an almost 
identical system, when compared to the CNT-Lipid nanostructure without Aspirin. 
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5.2 Preparing for drug release 
To test the drug release aspect of these new structures, a method was devised in order to 
monitor the sample over a period of several hours. The method, shown in Figure 17, 
involves centrifuging the nanostructures towards the base of the container, before 
blowing cold air onto the surface to reduce the water content slowly. This was done 
until a compact and semi-dry layer was present at the base of the cuvette, as can be seen 
in part D and E. These Aspirin filled nanostructures were taken and tested via 
Ultraviolet-visible spectroscopy to time the release of the aspirin contained inside. 
Figure 17 shows a diagram of the process used to create our time release experiment, 
with centrifugation used to pack the drug-filled nanostructure down, followed by the 
drop-wise addition of Millipore water, not to disturb the surface of the now film-like 
structure. UV-Vis spectroscopy can then be used to record a spectra every 30 minutes, 
to continually monitor the release of aspirin from its encasing nanostructure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: A) Stable CNT-Lipid Nanostructure B) Stable CNT-Lipid Nanostructure 
with 5mg Aspirin with foam from stirring c) Jouan B4 Centrifuge, used for making the 
residue in the cuvette. D) Cuvette containing a sediment of aspirin-containing CNT-
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lipid Nanostructure beneath an aqueous layer.  From this, the top layer is removed and 
the loaded residue is used for drug release.  E) Animated version showing release of 
Aspirin from Nanostructured sediment. 
 
5.3 Monitoring drug Release with UV-Vis 
Using Uv-Vis spectroscopy, we are able to record the spectrum every 30 minutes. These 
can be plotted together to show any trends in the spectra as shown below in Figures 18, 
19 and 20. 
 
 
Figure 18: UV Vis plot to show time release of drug, taken every 30 minutes for 
MWCNT-COOH stabilised lipid nanostructure, containing Aspirin. 
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Figure 19: UV Vis plot to show time release of drug, taken every 30 minutes for 
MWCNT-OH stabilised lipid nanostructure, containing Aspirin. 
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Figure 20: UV Vis plot to show time release of drug, taken every 30 minutes for 
SWCNT stabilised lipid nanostructure, containing Aspirin. 
 
From these release profiles, measured every 30 minutes, it seems to suggest that there is 
a larger release of the drug just before it releases fully. This could be due to the 
breakdown of the structure, releasing Aspirin rapidly through new holes forming in the 
walls of the encasement. MWCNT-COOH stabilised lipid nanostructures seemed to 
release most of its drug after around 19 hours, considerably more than the SWCNT 
which remained stable for only 6 hours. 
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5.4 Drug Release kinetics 
 
 
Figure 21: UV Vis plot to show time background, taken every 30 minutes for stabilised 
lipid nanostructure, containing no CNTs. 
 
Studying the data all at 294nm absorbance shows some interesting results also. Figures 
22, 23 and 24 show the repeatable results shown by UV-vis of each CNT. 
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Figure 22: Absorbance at 294nm vs time for MWCNT-COOH 
 
 
 
Figure 23: Absorbance at 294nm vs time for MWCNT-OH 
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Figure 24: Absorbance at 294nm vs time for SWCNT 
 
These give a good representation of the repeatability of the method, suggesting the 
uniformity of these release patterns. SWCNT has a much quicker release time when 
compared to CNT-OOH and CNT-OH, which could be useful in the case of releasing 
drugs more quickly in the body, rather than the requirement of slower release. 
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Although this method of Time Release monitoring could be heavily altered by the 
degradation of these film-like structures, the results from this show very consistent 
plots, all following a similar release pattern, making it very unlikely that random 
degradation of these structures is occurring, and making it more of a possibility that 
aspirin is being released over time in much the same way.  Each functionalization CNT 
had a different release pattern, and released fully over different extents of time, with 
SWCNT stabilised nanostructures fully releasing the aspirin in 6-8 hours, this being the 
slowest of the three. CNT-OH stabilised nanostructures taking much longer to release 
fully at 17 hours and CNT-OOH stabilised nanostructures fully releasing soon after that 
at 19 hours. These results were repeated and the plots remained the same, allowing us to 
draw the conclusion that the release times are specific to the functionality of the CNT 
and further studies could prove these slight structural differences can affect the 
properties of the nanostructure. 
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Chapter 6: Conclusions and Perspectives 
 
The field of nanoscience has been witnessing a rapid growth in the last decade. 
Recently, more and more, the attention of the community of nanoscientists has been 
focusing on technological applications. Nanotechnology has been emerging as an 
enabling technology, with high potential impact on virtually all fields of mankind 
activity (industrial, health-related, biomedical, environmental, economy, politics, etc.), 
yielding high expectations for a solution to the main needs of society, although having 
to address open issues with respect to its sustainability and compatibility. The fields of 
application of the research in nanoscience include aerospace, defense, national security, 
electronics, biology and medicine. There has been a significant progress in 
understanding achieved in recent years, both from the theoretical and experimental point 
of view, along with a strong interest to assess the current state of the art of this fast 
growing field, stimulating, at the same time, research collaboration among the different 
stakeholders in the area of nanoscience and the corresponding technological 
applications, prompting possibly the organization and presentation of joint projects in 
the near future involving both industry and public research. 
 
In my MSc study, we focused in particular on the biological and medical fields and 
described current and possible future developments in nanotechnological applications in 
such areas. Nanostructured, composite materials for drug delivery, biosensors, 
diagnostics and tumor therapy were reviewed here as examples. Carbon nanotubes were 
discussed as a primary example of emerging nanomaterials for many of the 
abovementioned applications. In this thesis, it has been made clear that Carbon 
Nanotubes, functionalised or not, have the ability to stabilise lipid nanoparticles in 
Millipore water. Through other simple methods this report has shown how the addition 
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of drugs such as Aspirin does not affect the overall stability of the system and does have 
possible uses in the pharmaceutical industry, providing toxicity of nanotubes in the 
body is not still an ongoing debate, a few years down the line. It can also be said that 
different functional groups definitely affect the long term stability of the system, and 
similarly viscosity could also be an issue, due to probe sonication not being able to 
function properly in thicker solutions. 
 
There are many future studies that could be of interest and benefit to the advancement in 
this area, due to CNTs fantastic array of properties. Specifically in this field of research, 
there are certainly more and more calls for toxicity studies into CNTs for 
pharmaceutical uses. Once a clear limit is given, I can see much more research going 
into CNTs for these types of uses, and huge advancements in all fields concerned could 
follow. 
 
If I personally could study further in this topic, I would like to simply repeat my 
experiments with different lipids, different drugs and many more functionalizations to 
create a catalogue of drug delivery options, specified to a particular route or organ. 
There are still thousands of combinations that have not had much attention, for example, 
the use of different Nanotubes. Using three types of CNTs is barely scraping the surface 
or the potential of this type of chemistry. 
 
Finally, I would like to see more studies into the hydrophobicity of each functionalised 
Nanotube, to form a database for the most likely to be able to be stabilised for long 
periods. 
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